APA (7th ed.) Citation

Sweeney, S., Laurence, Y. V., Berry, C., Singh, M. P., Dodd, M., Fielding, K., . . . Nyang'wa, B. (2025). 24-week, all-oral regimens for pulmonary rifampicin-resistant tuberculosis in TB-PRACTECAL trial sites: An economic evaluation. The Lancet global health, 13(2), e355-e363. https://doi.org/10.1016/S2214-109X(24)00467-4

Chicago Style (17th ed.) Citation

Sweeney, Sedona, et al. "24-week, All-oral Regimens for Pulmonary Rifampicin-resistant Tuberculosis in TB-PRACTECAL Trial Sites: An Economic Evaluation." The Lancet Global Health 13, no. 2 (2025): e355-e363. https://doi.org/10.1016/S2214-109X(24)00467-4.

MLA (9th ed.) Citation

Sweeney, Sedona, et al. "24-week, All-oral Regimens for Pulmonary Rifampicin-resistant Tuberculosis in TB-PRACTECAL Trial Sites: An Economic Evaluation." The Lancet Global Health, vol. 13, no. 2, 2025, pp. e355-e363, https://doi.org/10.1016/S2214-109X(24)00467-4.